{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-032263","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2026-07-07T12:54:20+00:00","discovered_at":"2026-07-07T12:55:01.344065+00:00","generated_at":"2026-07-07T12:55:05.497731+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"bioAffinity Technologies reports Q2 2026 CyPath Lung sales up >200% YoY, record quarter","bullets":["Q2 2026 CyPath Lung sales volume >200% YoY and >30% over Q1 2026.","Nearly 3,000 tests performed since commercial launch.","155% increase in physician offices ordering CyPath Lung vs Q2 2025.","Company expects to report Q2 2026 financial results in August.","Initiatives include longitudinal study, oncology expansion, asthma/COPD tests."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-032263","json":"https://secwatch.observer/filing/0001493152-26-032263.json","markdown":"https://secwatch.observer/filing/0001493152-26-032263.md","text":"https://secwatch.observer/filing/0001493152-26-032263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226032263/0001493152-26-032263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226032263/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T12:55:05.497731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}